<sup>18</sup>F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease

Ferda, Jiří; Ferdová, Eva; Baxa, Jan; Fínek, Jindřich; Topolčan, Ondřej

doi:10.21873/anticanres.12705

Cited by 11 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis was performed on 23 studies (Fig. 1), 11 concerning the staging phase [16,18,27,35,38,40,[44][45][46][47]52], and 12 the restaging phase [8,21,23,25,26,30,32,39,42,51,56,59]. Pooled sensitivities and specificities were obtained for the former (staging), and a pooled detection rate was computed for the latter (restaging).…”

Section: Quantitative Resultsmentioning

confidence: 99%

“…PET/MRI was used to seek biochemical recurrences of PCa in a total of 598 patients [8,26,32,34,39,42,51,52,56]. Taking the studies concerned together, the recurrent disease detection rate achieved with PET/MRI ranged between 54.5 [56] and 97% [8] (Table 2).…”

Section: Pet/mri In Cases Of Biochemical Disease Recurrencementioning

confidence: 99%

“…Radiolabeled choline PET/MRI was employed in the staging for 8/16 (50%) [11-14, 17, 29, 43, 53], while radiolabeled PSMA in 16/34 (47%) papers [16, 18, 27, 31, 35-37, 40, 44-49, 54]. Conversely, 5/16 (31%) [9,21,39,42,51] and 11/34 (32%) articles [8,23,25,26,28,30,32,34,52,56] were focused on the resting phase for radiolabeled choline and PSMA, respectively.…”

Section: Radiolabeled Psma Vs Radiolabeled Choline Pet/mrimentioning

confidence: 99%

See 2 more Smart Citations

PET/MRI in prostate cancer: a systematic review and meta-analysis

Evangelista

Zattoni

Cassarino

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Aim In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). Materials and methods A literature search was conducted in three different databases. The terms used were “choline” or “prostate-specific membrane antigen - PSMA” AND “prostate cancer” or “prostate” AND “PET/MRI” or “PET MRI” or “PET-MRI” or “positron emission tomography/magnetic resonance imaging.” All relevant records identified were combined, and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was < 10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table. Results Fifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients. Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively). Conclusions PET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease, particularly when radiolabeled PSMA was used.

show abstract

Section: Quantitative Resultsmentioning

confidence: 99%

Section: Pet/mri In Cases Of Biochemical Disease Recurrencementioning

confidence: 99%

Section: Radiolabeled Psma Vs Radiolabeled Choline Pet/mrimentioning

confidence: 99%

See 1 more Smart Citation

PET/MRI in prostate cancer: a systematic review and meta-analysis

Evangelista

Zattoni

Cassarino

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…One of the largest recent studies carried out by PROMETHEUS, a Multicentric European Study, confirmed PHI as one of the strongest predictors of PCa, correlating with the Gleason Score (GS). In our own studies, firstly monocentric [5,8] and later on multicentric (with our partners) [9,10], we proved the PHI's ability to distinguish between PCa GS < 7 (low aggressiveness) and GS ≥ 7 (higher aggressiveness).…”

Section: Phi As a Tool For The First (Initial) Stratification Of The Patientmentioning

confidence: 69%

Prostate Cancer Diagnostic Algorithm as a “Road Map” from the First Stratification of the Patient to the Final Treatment Decision

Sedlackova¹,

Dolejšová²,

Hora³

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

The diagnostics of prostate cancer are currently based on three pillars: prostate biomarker panel, imaging techniques, and histological verification. This paper presents a diagnostic algorithm that can serve as a “road map”: from initial patient stratification to the final decision regarding treatment. The algorithm is based on a review of the current literature combined with our own experience. Diagnostic algorithms are a feature of an advanced healthcare system in which all steps are consciously coordinated and optimized to ensure the proper individualization of the treatment process. The prostate cancer diagnostic algorithm was created using the prostate specific antigen and in particular the Prostate Health Index in the first line of patient stratification. It then continued on the diagnostic pathway via imaging techniques, biopsy, or active surveillance, and then on to the treatment decision itself. In conclusion, the prostate cancer diagnostic algorithm presented here is a functional tool for initial patient stratification, comprehensive staging, and aggressiveness assessment. Above all, emphasis is placed on the use of the Prostate Health Index (PHI) in the first stratification of the patients as a predictor of aggressiveness and clinical stage of prostrate cancer (PCa). The inclusion of PHI in the algorithm significantly increases the accuracy and speed of the diagnostic procedure and allows to choose the optimal pathway just from the beginning. The use of advanced diagnostic techniques allows us to move towards to a more advanced level of cancer care. This diagnostics algorithm has become a standard of care in our hospital. The algorithm is continuously validated and modified based on our results.

show abstract

“…Previous publications reported on overall detection rates for FCH or 11C-choline PET/MRI in recurrent PCa [2,[16][17][18]. For instance, Eiber et al [16] found an overall detection rate of 84% in 75 patients with median PSA levels of 2.6 ng/mL (range 0.2-88 ng/mL).…”

Section: Discussionmentioning

confidence: 99%

Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer

et al. 2021

View full text Add to dashboard Cite

Objectives The aims of the study were (i) to examine the PCa detection rate of 18F-choline (FCH) PET/MRI and (ii) to assess the impact of PET/MRI findings in patients with PCa who develop OMD using PSA response as a biomarker. Methods We retrospectively analyzed a cohort of 103 patients undergoing FCH PET/MRI for biochemical recurrence of PCa. The inclusion criteria were (1) previous radical prostatectomy (RP) with or without adjuvant radiotherapy (RT); (2) PSA levels available at the time of PET; (3) OMD, defined as a maximum of 5 lesions on PET/MRI; and (4) follow-up data available for at least 6 months after PET. All images were reviewed by two nuclear medicine physicians and interpreted with the support of two radiologists. Results Seventy patients were eligible for the study: 52 patients had a positive FCH PET/MRI and 18 had a negative scan. The overall PCa detection rates for MRI, PET, and PET/MRI were 65.7%, 37.1%, and 74.3%, respectively. Thirty-five patients were treated with radiotherapy (RT), 16 received hormonal therapy (HT), 3 had a combined therapy (RT + HT), and 16 (23%) underwent PSA surveillance. At follow-up, PSA levels decreased in 51 patients (73%), most of whom had been treated with RT or RT + HT. Therapeutic management was guided by PET/MRI in 74% of patients, which performed better than MRI alone (68% of patients). Conclusion FCH PET/MRI has a higher detection rate than MRI or PET alone for PCa patients with OMD and PSA levels > 0.5 ng/mL, prompting a better choice of treatment.

show abstract

¹⁸F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease

Abstract: F-FCH-PET/MRI using an integrated system with 1,25 MBq/kg dosing of FCH is a valuable tool in evaluation of restaging in patients with prostatic carcinoma, with high detection rate even in those with a low serum PSA level.

Cited by 11 publications

References 14 publications

PET/MRI in prostate cancer: a systematic review and meta-analysis

PET/MRI in prostate cancer: a systematic review and meta-analysis

Prostate Cancer Diagnostic Algorithm as a “Road Map” from the First Stratification of the Patient to the Final Treatment Decision

Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer

Contact Info

Product

Resources

About

18F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease

Abstract: F-FCH-PET/MRI using an integrated system with 1,25 MBq/kg dosing of FCH is a valuable tool in evaluation of restaging in patients with prostatic carcinoma, with high detection rate even in those with a low serum PSA level.

Cited by 11 publications

References 14 publications

PET/MRI in prostate cancer: a systematic review and meta-analysis

PET/MRI in prostate cancer: a systematic review and meta-analysis

Prostate Cancer Diagnostic Algorithm as a “Road Map” from the First Stratification of the Patient to the Final Treatment Decision

Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer

Contact Info

Product

Resources

About

¹⁸F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease